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Sex Med 2Introduction: Ospemifene (Osphena, Shionogi Inc, Florham, NJ, USA) is an estrogen agonist and antagonist
approved by the U.S. Federal Drug Administration for the treatment of “moderate to severe dyspareunia, a
symptom of vulvar and vaginal atrophy, due to menopause.” Although published, peer-reviewed, placebo-
controlled studies have shown objective improvement in dyspareunia and in vaginal atrophy, there are no
published data that have assessed changes in vulvar atrophy after the use of ospemifene.
Aim: To present two cases of women with severe vulvar atrophy that showed no improvement with the use of
ospemifene.
Methods: A review of two recent cases of a clinic specializing in the treatment of vulvovaginal disorders was
performed. Case 1 was a 53-year-old menopausal woman who presented with non-provoked vulvar and vaginal
discomfort and introital dyspareunia. She had used ospemifene 60 mg/d for 1.5 years without improvement in
her symptoms before presentation. Case 2 was a 57-year-old menopausal woman who also presented with
non-provoked vulvar rawness, burning, irritation, vaginal dryness, and introital dyspareunia. She had started
ospemifene 60 mg/d 1 year before presentation and reported mild improvement in her vaginal dryness but no
improvement in her vulvar irritation or introital dyspareunia.
Main Outcome Measures: Change in vulvar atrophy and introital dyspareunia.
Conclusion: These cases highlight the need to perform additional clinical trials that speciﬁcally assess the efﬁcacy
of ospemifene for changes in vulvar atrophy.
Sex Med 2016;4:e217ee220. Copyright  2016, The Authors. Published by Elsevier Inc. on behalf of the Inter-
national Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Ospemifene (Osphena; Shionogi Inc, Florham NJ, USA) is a
selective estrogen-receptor modulator that has been approved by
the Food and Drug Administration for the treatment of mod-
erate to severe vulvar and vaginal atrophy and moderate to severe
dyspareunia (a symptom of vulvovaginal atrophy) with a
suggested dosage of 60 mg once daily.1 The prescribing guide-
lines for ospemifene are based on two 12-week, double-blinded,
placebo-controlled, parallel-group efﬁcacy trials and one double-
blinded, placebo-controlled, parallel-group, 52-week long-term
safety trial.cember 16, 2015. Accepted May 17, 2016.
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i.org/10.1016/j.esxm.2016.05.002
016;4:e217ee220The ﬁrst clinical trial was a 12-week, double-blinded, placebo-
controlled, parallel-group efﬁcacy trial that included 826
menopausal women in three randomized groups.1,2 The ﬁrst
group received ospemifene 30 mg/d for 12 weeks (n ¼ 282), the
second group received ospemifene 60 mg/d for 12 weeks
(n ¼ 276), and the third group received a placebo (n ¼ 268).
The co-primary end points included the mean change from
baseline in vaginal dryness or dyspareunia as indicated on a four-
point scoring system, with participants stratiﬁed and assessed by
the symptoms that were most bothersome at baseline (none ¼ 0,
mild ¼ 1, moderate ¼ 2, severe ¼ 3) as taken at the screening
appointment and again at weeks 4 and 12. Vaginal dryness was
further assessed by the percentage of superﬁcial cells and para-
basal cells and vaginal pH as seen on a vaginal culture wet
mount. The results of the trial indicated that women who
received ospemifene in the two strata showed an improvement
from baseline in vaginal dryness or dyspareunia by the four-point
scale and an improvement in total Female Sexual Function Index
score that was evident at week 4 and increased in magnitude
until week 12.e217
Figure 1. Severe atrophy of vulvar vestibule of a patient taking
ospemifene.
e218 Goldstein and KingThe second clinical trial was a 12-week, double-blinded,
placebo-controlled, parallel-group efﬁcacy and safety trial that
included 919 generally healthy postmenopausal women diag-
nosed with vulvovaginal atrophy who had greater than or equal
to 5% superﬁcial cells on vaginal smear and a vaginal pH
higher than 5.0.1,3 The participants were stratiﬁed into two
groups based on the symptoms they designated as most both-
ersome at baseline; the ﬁrst group included those who were
most bothered by vaginal dryness (dryness cohort) and the
second group included those who were most bothered by pain
with intercourse (dyspareunia cohort). Treatment groups
included those who received ospemifene 60 mg/d for 12 weeks
(n ¼ 463) and those who received a placebo (n ¼ 456). The
co-primary end points included the mean change from baseline
in their most bothersome symptoms, which were vulvar and/or
vaginal dryness (combined as one variable) and dyspareunia as
indicated on a four-point scoring system. Secondary end points
included change from baseline in the domains of the Female
Sexual Function Index as taken at weeks 4 and 12 and change
from baseline in serum sex hormone levels (follicle-stimulating
hormone, luteinizing hormone, and SHBG) collected at the
screening appointment and at week 12. The results of this trial
showed that signiﬁcantly more women who reported dyspar-
eunia as their most bothersome symptom had improvement
(68.3% vs 54.1%; P ¼ .0255) or relief (57.5% vs 41.8%;
P ¼ .0205) in the severity of their dyspareunia from baseline
compared with week 12 with ospemifene use vs placebo.
Participants with vulvar and/or vaginal dryness also had
improvement (74.6% vs 57.7%; P ¼ .0101), substantial
improvement (42.4% vs 26.9%; P ¼ .0172), and even relief
(66.1% vs 49.0%; P ¼ .0140) of their vulvar and/or vaginal
dryness from baseline to week 12 with ospemifene use
compared with placebo.
The third clinical trial was a 52-week, double-blinded,
placebo-controlled, parallel-group extension safety trial that
was conducted in 301 women 40 to 80 years old without a
uterus who were recruited from the 12-week efﬁcacy study.4
The total elapsed time for patients was 68 weeks, including
the initial 12-week study, the extension of 52 weeks, and a
post-trial follow-up after 4 weeks. Women continued the
60-mg/d ospemifene dose or switched from the blinded placebo
or 30-mg/d ospemifene dose to the open-label 60-mg/d ospe-
mifene dose. Safety assessments included adverse events, labo-
ratory studies, physical and gynecologic examination, vital signs,
breast palpation, and mammography. Ospemifene was found to
be clinically safe and generally well tolerated in postmenopausal
patients with dyspareunia.
The two efﬁcacy studies included an objective assessment
of vaginal atrophy, However, somewhat surprisingly, ospe-
mifene had been approved for (and is currently being mar-
keted as) a treatment for vaginal and vulvar atrophy, although
none of the published trials included any objective assessment
of the vulvar tissue. Examples of tests that could have beenincluded are quantitative sensory testing and changes in
mucosal thickness as measured by biopsy examinations before
and after treatment.
This report describes two cases of postmenopausal women
who used ospemifene for at least 1 year and found no
improvement in vulvar atrophy or introital allodynia.CASE 1
The patient was a 53-year-old gravida 1, para 2, aborta
0 menopausal woman who presented to a clinic specializing in
the treatment of vulvovaginal disorders with complaints of
non-provoked vulvar and vaginal rawness and pain with inter-
course that she described as burning pain upon penetration. She
reported that her symptoms had become progressively worse
during the past 5 years. She had been menopausal for 10 years
and had pain-free intercourse with normal lubrication and sexual
arousal before the past 5 years. She had tried an estradiol vaginal
ring and estradiol intravaginal tablets, without improvement in
her symptoms. For the past 1.5 years, she had been taking
ospemifene 60 md/d, without improvement in her symptoms.
On physical examination, the patient had profound atrophy,
erythema—especially of the major and minor vestibular gland
ostia—and severe tenderness of the vulvar vestibule (Figure 1).
There was no evidence of vulvar dermatoses. The vaginal mucosa
was mildly atrophic and non-tender, without ulcerations or
erosions. The bladder and urethra were non-tender to palpation.
The levator ani muscles were not signiﬁcantly tight or tender.
The vaginal pH was 5.0, and a saline wet mount showed
predominantly mature squamous cells with few leukocytes and
few parabasal cells.Sex Med 2016;4:e217ee220
Figure 2. Severe atrophy of the vulvar vestibule with erythema of
the gland ostia and clitoral atrophy.
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The patient was a 53-year-old gravida 5, para 3, aborta 2
menopausal woman who presented with the complaint of
non-provoked vulvovaginal rawness, burning, dryness, and irrita-
tion. In addition, she complained of severe insertional dyspareunia
of 2.5 years’ duration. Her dyspareunia was so severe that she had
not engaged in sexual intercourse for 16 months. The patient had
been experiencing severe hot ﬂashes and night sweats since she
became menopausal 3 years previously. She had been treated with
water- and silicon-based lubricants, topical lidocaine ointment,
topical metronidazole, ﬂuconazole, topical miconazole, and coco-
nut oil, with minimal improvement in her provoked or non-
provoked allodynia. In addition, at presentation, she had been
taking ospemifene 60 mg/d for the past 13 months. She reported
that her vaginal pain had been alleviated slightly within 3 months
after starting the ospemifene, but she continued to have signiﬁcant
provoked, and non-provoked, vulvar pain. The patient’s historywas
signiﬁcant for menorrhagia, for which she had an endometrial
ablation. In addition, she had a history of anxiety, depression, and
bulimia that she attributed to a previous abusive relationship, and
she was currently taking escitalopram 10 mg/d. Genitourinary ex-
amination showednormal labiamajora, normal interlabial sulci, and
a normal clitoral prepuce. The labia minora and glans clitoris were
mildly atrophic. The vulvar vestibule was severely erythematous,
severely atrophic, and severely tender throughout, without lesions,
ulcerations, or erosions (Figure 2). There was no evidence of vulvar
dermatoses. The vaginal mucosa was well estrogenized and non-
tender, without ulcerations or erosions. The vaginal pH was 4.0.
Saline wet mount showed all mature squamous without parabasal
cells. There were few white blood cells and fewer than 5% clue cells.
Lactobacilli were present and therewere no fungal elements present.DISCUSSION
Ospemifene was recently approved by the Food and Drug
Administration for the treatment of moderate to severe dyspar-
eunia and moderate to severe vulvar and vaginal atrophy.1 How-
ever, the published trials on which the prescribing indications are
based only reported changes from baseline in vaginal dryness and
dyspareunia and changes in Female Sexual Function Index
scores.2e4 These studies did not include any primary or secondary
end points that exclusively examined vulvar symptoms: the
assessment of the most bothersome symptom combined the
symptoms of vulvar and vaginal atrophy. In addition, there were no
objective measurements of vulvar atrophy such as quantitative
sensory testing or post-treatment histologic evaluation.
These two case studies provide evidence that ospemifene does
not treat vulvar atrophy or introital dyspareunia. Although no
medication can be expected to be efﬁcacious in all patients, there is
a complete absence of published data that show that ospemifene
does treat vulvar atrophy, and the present cases represent the only
data currently available to prescribing providers. At the very least,
these cases illustrate the need for additional studies that speciﬁcallySex Med 2016;4:e217ee220examine vulvar atrophy and introital dyspareunia. For example,
these studies could examine change in vulvar vestibular pain
threshold before and after treatment with ospemifene as measured
by a calibrated instrument such as a vulvogeisometer.5
It is also plausible that ospemifene, a selective estrogen
receptor modulator, does not signiﬁcantly reverse atrophy of the
vulvar vestibule because the non-keratinized, squamous endo-
thelium of the vulvar vestibule is highly androgen dependent.6,7
In addition, the Bartholin glands, Skene glands, and minor
vestibular glands are androgen-dependent mucin-secreting
glands. To date, there are no published data that have examined
the interaction between ospemifene and the androgen receptor
(AR). In contrast, lasofoxifene, another selective estrogen recep-
tor modulator, has shown agonist activity of the AR.8 Unless
ospemifene acts as an AR agonist, it is unlikely that it will
signiﬁcantly reverse vulvar atrophy or introital dyspareunia.
It should be noted that in case 1, the patient’s vulvar at-
rophy and introital dyspareunia were not alleviated with the
use of an estradiol-containing vaginal ring (Estring; Pﬁzer,
New York, NY, USA) or an estradiol-containing vaginal tablet
(Vagifem; Novo Nordisk, Plainsboro, NJ, USA). However,
neither of these products has been approved for the indication
of vulvar atrophy. If one considers the embryologic and
anatomic differences between the vagina and the vulva, this is
not surprising, primarily because the blood supply of the vulva
is different from that of the vagina. Therefore, because neither
product provides estradiol in a dose large enough for
e220 Goldstein and Kingsigniﬁcant systemic absorption, it would be unlikely that
either product would alleviate vulvar atrophy. This is in
contrast to cream-based estradiol products that can be applied
directly to the vulva or can leak out of the vaginal lumen and
then come in contact with the vulvar endothelium.
In addition, recent studies have shown that creams that
contain testosterone (alone or in combination with estrogen)
are superior in treating female sexual dysfunction in meno-
pausal women with genitourinary syndrome of menopausal
(previously known as vulvovaginal atrophy) than creams that
contain only estrogen.9,10 Therefore, the results of these
studies clearly illustrate the need for studies on the activity of
ospemifene on the AR.Corresponding Author: Andrew Goldstein, Center for
Vulvovaginal Disorders, 3 Washington Circle NW, Suite 205,
Washington, DC 20037, USA. Tel: 202-887-0568; Fax: 202-
659-6481; E-mail: obstetrics@yahoo.com
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